From: Association of serum osteoprotegerin with vascular calcification in patients with type 2 diabetes
 | Stage 1 | Stage 2 | Stage 3 | Stage 4 | P value |
---|---|---|---|---|---|
Subjects (male/female) | 59(42/17) | 40(24/16) | 19(17/2) | 6(5/1) | Â |
Serum creatinine (mg/dl) | 0.73±0.02 | 0.81±0.03 | 0.87±0.03* | 1.2±0.10**,##,$$ | < 0.001 |
eGFR (ml/min) | 80.1±2.6 | 69.3±2.9* | 68.7±4.0 | 46.5±3.2**,# | <0.001 |
Albuminuria (mg/g creatinine) | 12.4±1.1 | 95.0±10.7** | 483.8±63.6**,## | 538.0±98.4**,## | <0.001 |
Serum osteoprotegerin (pg/ml) | 183.8±117.5 | 329.6±227.4 | 168.1±87.2 | 59.8±27.6 | 0.876 |
Serum osteocalcin (ng/ml) | 1.58±0.21 | 1.79±0.26 | 1.35 ±0.32 | 2.06 ±0.76 | 0.696 |
Serum 25-hydroxyvitamin D3 (nmol/l) | 85.3±5.71 | 86.2±6.52 | 103.3±14.9 | 81.1±18.8 | 0.516 |
Serum FGF23 (pg/ml) | 32.6±1.83 | 33.2±3.53 | 36.1±3.57 | 58.7±7.08** | 0.007 |
No calcification, n | 41 | 26 | 13 | 5 | Â |
Calcification, n | 18 | 14 | 4 | 1 | Â |